AstraZeneca has acquired a portfolio of neuroscience assets from Link Medicine, which focuses on the field of autophagy, an intracellular process that clears and recycles misfolded proteins, for developing potential new treatments for neurodegenerative diseases. AZ will make an upfront and milestone payments and will assume all R&D activities. The financial terms were not disclosed.   AZ acquired multiple small molecule assets in clinical and preclinical stage that target the enzyme farnesyl...